[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100379879":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":35,"centralContacts":40,"locations":49,"responsibleParty":61,"collaborators":63,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":30,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":52,"whyStopped":30,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"The Institute of Molecular and Translational Medicine, Czech Republic","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Self-sampling device sent at home","ACTIVE_COMPARATOR","Women randomly selected from a commercial vendor database (both attenders and non-attenders) receive a mail inviting them to perform a cervicovaginal self-sampling at their home (with the device provided). Returned self-sampled swabs will be tested by CE-IVD-marked (Conformité Européenne, In Vitro Diagnostics) HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.",[13],"Diagnostic Test: Self-sampling by Evalyn Brush",{"label":15,"type":16,"description":17,"interventionNames":18},"Self-sampling device sent by gynecologist(s)","EXPERIMENTAL","Women selected from databases of cooperating gynecologists (non-attenders for at least 3 years) receive a mail inviting them to perform a cervicovaginal self-sampling at their home (with the device provided). Returned self-sampled swabs will be tested by CE-IVD-marked HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.",[13],{"label":20,"type":16,"description":21,"interventionNames":22},"Self-sampling device obtained from general practitioner(s)","Women selected from databases of cooperating general practitioners (non-attenders for at least 3 years) receive a self-sampling device. Returned self-sampled swabs will be tested by CE-IVD-marked HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.",[23],"Diagnostic Test: Self sampling by Evalyn Brush home or in GP´s clinic",[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DIAGNOSTIC_TEST","Self-sampling by Evalyn Brush","Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.",[9,15],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Self sampling by Evalyn Brush home or in GP´s clinic","Women will perform a cervicovaginal self-sampling at their home or the GP´s clinic using Evalyn Brush",[20],[36],{"name":37,"affiliation":38,"role":39},"Marian Hajduch, MD, PhD.","IMTM, Palacky University in Olomouc, Faculty of Medicine and Dentistry","STUDY_DIRECTOR",[41,45],{"name":37,"role":42,"phone":43,"phoneExt":30,"email":44},"CONTACT","+420 585 632 083","marian.hajduch@upol.cz",{"name":46,"role":42,"phone":47,"phoneExt":30,"email":48},"Vladimira Koudelakova, MSc, Ph.D.","+420 585 632 089","vladimira.koudelakova@upol.cz",[50],{"facility":51,"status":52,"city":53,"state":30,"zip":30,"country":54,"countryCode":30,"cosmosGeoPoint":55,"geoPoint":60,"contacts":30},"University Hospital Olomouc","RECRUITING","Olomouc","Czechia",{"type":56,"coordinates":57},"Point",[58,59],17.25175,49.59552,{"lat":59,"lon":58},{"type":62,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR",[64],{"name":65,"class":6},"National Institute for Cancer Research, Czech Republic","100379879","self-sampling-for-non-attenders-to-cervical-cancer-screening-100379879",false,"NCT04226313","Self-sampling for Non-attenders to Cervical Cancer Screening","Cervical Cancer Prevention Using Self-sampling and Human Papillomavirus Detection","KOPRETINA","Inclusion Criteria:\n\n* Women with age 30-65 years; for arm A women \\> 65 years are allowed\n* Women live in the Czech Republic.\n* Women who have not participate in cervical cancer screening program in the Czech Republic for at least 3 years (Arm B and C).\n* Women with completed informed consent.\n* Women capable of self-sampling of cervicovaginal swab.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Women with no sexual intercourse experience.\n* Women after hysterectomy including cervix.",true,"FEMALE","30 Years","65 Years",{"count":79,"type":80},15000,"ESTIMATED","INTERVENTIONAL",[83],"NA","The trial will evaluate whether self-sampling and human papillomavirus (HPV) testing may increase cervical cancer screening attendance among under-screened women in Czech Republic. Different ways of offering self-sampling device will be evaluated.",[86,87,88],"Cervical Cancer","Cervical Dysplasia","Human Papillomavirus Infection",[90,91,92,93,94,95],"human papillomavirus","HPV","self-sampling","cervicovaginal swab","cervical cancer screening","non-attendance","2026-03-19",{"date":98,"type":99},"2026-03-23","ACTUAL",{"date":101,"type":99},"2019-09-23",{"date":103,"type":80},"2026-12-01",{"name":5,"class":6},1]